Latest & greatest articles for depression

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on depression or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on depression and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for depression

1. Psychological therapies for the treatment of depression in chronic obstructive pulmonary disease. (PubMed)

Psychological therapies for the treatment of depression in chronic obstructive pulmonary disease. BACKGROUND: Chronic obstructive pulmonary disease (COPD) has been recognised as a global health concern, and one of the leading causes of morbidity and mortality worldwide. Projections of the World Health Organization (WHO) indicate that prevalence rates of COPD continue to increase, and by 2030, it will become the world's third leading cause of death. Depression is a major comorbidity amongst (...) patients with COPD, with an estimate prevalence of up to 80% in severe stages of COPD. Prevalence studies show that patients who have COPD are four times as likely to develop depression compared to those without COPD. Regrettably, they rarely receive appropriate treatment for COPD-related depression. Available findings from trials indicate that untreated depression is associated with worse compliance with medical treatment, poor quality of life, increased mortality rates, increased hospital admissions

2019 Cochrane

2. Effect of Integrated Behavioral Weight Loss Treatment and Problem-Solving Therapy on Body Mass Index and Depressive Symptoms Among Patients With Obesity and Depression: The RAINBOW Randomized Clinical Trial. (PubMed)

Effect of Integrated Behavioral Weight Loss Treatment and Problem-Solving Therapy on Body Mass Index and Depressive Symptoms Among Patients With Obesity and Depression: The RAINBOW Randomized Clinical Trial. Importance: Coexisting obesity and depression exacerbate morbidity and disability, but effective treatments remain elusive. Objective: To test the hypothesis that an integrated collaborative care intervention would significantly improve both obesity and depression at 12 months compared (...) participants randomly assigned to the intervention (n = 204) or the usual care control group (n = 205) received medical care from their personal physicians as usual, received information on routine services for obesity and depression at their clinic, and received wireless physical activity trackers. Intervention participants also received a 12-month intervention that integrated a Diabetes Prevention Program-based behavioral weight loss treatment with problem-solving therapy for depression and, if indicated

2019 JAMA

3. Effect of Multinutrient Supplementation and Food-Related Behavioral Activation Therapy on Prevention of Major Depressive Disorder Among Overweight or Obese Adults With Subsyndromal Depressive Symptoms: The MooDFOOD Randomized Clinical Trial. (PubMed)

Effect of Multinutrient Supplementation and Food-Related Behavioral Activation Therapy on Prevention of Major Depressive Disorder Among Overweight or Obese Adults With Subsyndromal Depressive Symptoms: The MooDFOOD Randomized Clinical Trial. Importance: Effects of nutritional interventions on the prevention of major depressive disorder (MDD) in overweight adults are unknown. Objective: To examine the effect of 2 nutritional strategies (multinutrient supplementation, food-related behavioral (...) activation therapy) and their combination for prevention of a new MDD episode in overweight adults with subsyndromal depressive symptoms. Design, Setting, and Participants: This multicenter 2 × 2 factorial randomized clinical trial included overweight adults (body mass index, 25-40) with elevated depressive symptoms (Patient Health Questionnaire-9 [PHQ-9] scores ≥5) and no MDD episode in the past 6 months from 4 European countries. A total of 1025 adults were randomized (July 30, 2015-October 12, 2016

2019 JAMA

4. Internet-Delivered Cognitive Behavioural Therapy for Major Depression and Anxiety Disorders

Internet-Delivered Cognitive Behavioural Therapy for Major Depression and Anxiety Disorders Internet-Delivered Cognitive Behavioural Therapy for Major Depression and Anxiety Disorders - Health Quality Ontario (HQO) Let's make our health system healthier Open Menu Quick Links Search Search A A A Evidence to Improve Care Share: Internet-Delivered Cognitive Behavioural Therapy for Major Depression and Anxiety Disorders Final Recommendation Health Quality Ontario, under the guidance of the Ontario (...) Health Technology Advisory Committee, recommends publicly funding guided internet-delivered cognitive behavioural therapy for mild to moderate major depression and anxiety disorders Cognitive behavioural therapy (or “CBT”) is a form of psychotherapy that has proven effective in treating major depression and anxiety disorders. However, it can often be difficult for people to access this therapy because of long wait times, the cost of sessions, and travel time to get to sessions. Cognitive

2019 Health Quality Ontario

5. Vagus nerve stimulation for chronic major depressive episodes

Vagus nerve stimulation for chronic major depressive episodes Public Summary Document Application No. 1491 - Vagus Nerve Stimulation (VNS) for chronic major depressive episodes Applicant: LivaNova Australia Pty Ltd Date of MSAC consideration: MSAC 73 rd Meeting, 26-27 July 2018 Context for decision: MSAC makes its advice in accordance with its Terms of Reference, visit the MSAC website 1. Purpose of application An application requesting Medicare Benefit Schedule (MBS) listing for Vagus Nerve (...) Stimulation (VNS) for chronic major depressive episodes was received from LivaNova Australia Pty Ltd by the Department of Health. 2. MSAC’s advice to the Minister After considering the strength of the available evidence in relation to comparative safety, clinical effectiveness and cost-effectiveness, MSAC did not support MBS funding of VNS for chronic major depressive episodes. MSAC accepted that there was a clinical need for more treatment options for this patient population. However, MSAC had concerns

2019 Medical Services Advisory Committee

6. Comparative Efficacy of Therapies for Treatment of Depression for Patients Undergoing Maintenance Hemodialysis: A Randomized Clinical Trial. (PubMed)

Comparative Efficacy of Therapies for Treatment of Depression for Patients Undergoing Maintenance Hemodialysis: A Randomized Clinical Trial. Background: Although depression is common among patients receiving maintenance hemodialysis, data on their acceptance of treatment and on the comparative efficacy of various therapies are limited. Objective: To determine the effect of an engagement interview on treatment acceptance (phase 1) and to compare the efficacy of cognitive behavioral therapy (CBT (...) ) versus sertraline (phase 2) for treating depression in patients receiving hemodialysis. Design: Multicenter, parallel-group, open-label, randomized controlled trial. (ClinicalTrials.gov: NCT02358343 ). Setting: 41 dialysis facilities in 3 U.S. metropolitan areas. Participants: Patients who had been receiving hemodialysis for at least 3 months and had a Beck Depression Inventory-II score of 15 or greater; 184 patients participated in phase 1, and 120 subsequently participated in phase 2. Interventions

2019 Annals of Internal Medicine

7. Management of perinatal depression with non-drug interventions. (PubMed)

Management of perinatal depression with non-drug interventions. Perinatal depression is a common disorder that has been associated with serious risks to mother and child. Recently, screening for depression in pregnant and postpartum women has increased, as has the development of new psychotherapy and non-drug treatment modalities. Matching patients to treatments can be challenging, and although research into personalized treatment of major depression in the general population has increased (...) , no published guidelines focus on personalized treatment approaches to perinatal depression. In particular, guidelines on non-drug treatments are lacking. This review summarizes the evidence on personalized non-drug treatment of perinatal depression, how to incorporate patients' preferences, novel treatments under investigation, and the potential role of biomarkers in matching patients to treatment. The review provides recommendations for future research in personalized care of perinatal depression

2019 BMJ

8. Interventions to Prevent Perinatal Depression: Evidence Report and Systematic Review for the US Preventive Services Task Force. (PubMed)

Interventions to Prevent Perinatal Depression: Evidence Report and Systematic Review for the US Preventive Services Task Force. Importance: Depression during pregnancy and the postpartum period is relatively common and can have adverse effects on both mother and child. Objective: To systematically review benefits and harms of primary care-relevant interventions to prevent perinatal depression, a major or minor depressive episode during pregnancy or up to 1 year after childbirth, to inform (...) the US Preventive Services Task Force. Data Sources: MEDLINE, PubMED (for publisher-supplied records only), PsycINFO, and the Cochrane Central Register of Controlled Trials; surveillance through December 5, 2018. Study Selection: Randomized clinical trials (RCTs) and nonrandomized controlled intervention studies of interventions (eg, behavior-based, antidepressants, dietary supplements) to prevent perinatal depression in general populations of pregnant and postpartum individuals or in those

2019 JAMA

9. Interventions to Prevent Perinatal Depression: US Preventive Services Task Force Recommendation Statement. (PubMed)

Interventions to Prevent Perinatal Depression: US Preventive Services Task Force Recommendation Statement. Importance: Perinatal depression, which is the occurrence of a depressive disorder during pregnancy or following childbirth, affects as many as 1 in 7 women and is one of the most common complications of pregnancy and the postpartum period. It is well established that perinatal depression can result in adverse short- and long-term effects on both the woman and child. Objective: To issue (...) a new US Preventive Services Task Force (USPSTF) recommendation on interventions to prevent perinatal depression. Evidence Review: The USPSTF reviewed the evidence on the benefits and harms of preventive interventions for perinatal depression in pregnant or postpartum women or their children. The USPSTF reviewed contextual information on the accuracy of tools used to identify women at increased risk of perinatal depression and the most effective timing for preventive interventions. Interventions

2019 JAMA

10. Postnatal depression

Postnatal depression Postnatal depression - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Postnatal depression Last reviewed: January 2019 Last updated: February 2019 Summary Refers to the development of a depressive illness following childbirth and may form part of a unipolar or, less frequently, a bipolar illness. The Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) does not recognise (...) postnatal depression as a separate diagnosis; rather, patients must meet the criteria for a major depressive episode and the criteria for the perinatal-onset specifier. The definition according to DSM-5 is, therefore, a major depressive episode with an onset in pregnancy or within 4 weeks of delivery. However there is no established consensus as to the length of postnatal period, and some authorities define postnatal depression as occurring within the first 12 months after delivery. Aetiology is poorly

2019 BMJ Best Practice

11. Standardized Library of Depression Outcome Measures

Standardized Library of Depression Outcome Measures Standardized Library of Depression Outcome Measures | Effective Health Care Program Search Effective Health Care website Submit search Toggle navigation Select site to search Search Effective Health Care website Submit search Standardized Library of Depression Outcome Measures Michelle B. Leavy, M.P.H. Fang Li, MD, M.S. * OM1 On behalf of the Outcome Measures Framework (OMF) Depression Workgroup. Abstract Significant variation exists in both (...) conditions; it is intended to serve as a content model for developing harmonized outcome measures for specific clinical areas. AHRQ assessed the feasibility of using the OMF to develop standardized libraries of outcome measures in five clinical areas: atrial fibrillation, asthma, depression, lung cancer, and lumbar spondylolisthesis. These clinical areas represent diverse populations and care settings, different treatment modalities, and varying levels of harmonization. For each clinical area

2019 Effective Health Care Program (AHRQ)

12. Perinatal Depression: Preventive Interventions

Perinatal Depression: Preventive Interventions Final Update Summary: Perinatal Depression: Preventive Interventions - US Preventive Services Task Force Search USPSTF Website Text size: Assembly version: 1.0.0.308 Last Build: 11/16/2018 6:27:19 PM You are here: Final Summary Perinatal Depression: Preventive Interventions Release Date: February 2019 Recommendation Summary Population Recommendation Grade Pregnant and postpartum persons The USPSTF recommends that clinicians provide or refer (...) pregnant and postpartum persons who are at increased risk of perinatal depression to counseling interventions. To read the recommendation statement in JAMA , select . To read the evidence summary in JAMA , select . See the for information on risk assessment. ( ) Related Information for Consumers Related Information for Health Professionals There is no related information for health professionals. Supporting Documents ( ) ( ) Clinical Summary Clinical summaries are one-page documents that provide

2019 U.S. Preventive Services Task Force

13. The depressing evidence for antidepressants in the elderly

The depressing evidence for antidepressants in the elderly Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 5,000 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care research. www.acfp.ca February 4 (...) , 2019 The depressing evidence for antidepressants in the elderly Clinical Question: How effective are antidepressants for treating depression in the elderly? Bottom Line: The efficacy of antidepressants in the elderly is inconsistent and may decrease as patients age. From 80% to 40% of elderly patients will recover with antidepressants, with some studies showing no difference from placebo response rates. Harms of antidepressants are common, with ~20% stopping due to adverse effects. Evidence: • 5

2019 Tools for Practice

14. Effects of Sahaj Samadhi meditation on heart rate variability and depressive symptoms in patients with late-life depression

Effects of Sahaj Samadhi meditation on heart rate variability and depressive symptoms in patients with late-life depression 30482255 2018 11 28 1472-1465 2018 Nov 28 The British journal of psychiatry : the journal of mental science Br J Psychiatry Effects of Sahaj Samadhi meditation on heart rate variability and depressive symptoms in patients with late-life depression. 1-7 10.1192/bjp.2018.265 Late-life depression (LLD) is a disabling disorder and antidepressants are ineffective in as many (...) as 60% of cases. Converging evidence shows a strong correlation between LLD and subsequent risk of cardiovascular disease. There is a need for new, well-tolerated, non-pharmacological augmentation interventions that can treat depressive symptoms as well as improve heart rate variability (HRV), an important prognostic marker for development of subsequent cardiovascular disease. Meditation-based techniques are of interest based on positive findings in other samples.AimsWe aimed to assess the efficacy

2019 EvidenceUpdates

15. Antidepressants do not help treat depression in people living with dementia

Antidepressants do not help treat depression in people living with dementia Antidepressants do not help treat depression in dementia Dissemination Centre Discover Portal NIHR DC Discover Antidepressants do not help treat depression in people living with dementia Published on 8 January 2019 doi: Antidepressants do not reduce symptoms of depression in people with dementia compared with placebo (dummy pills). Measured 6 to 13 weeks after starting the treatment, there is little or no difference (...) is reliable. This review supports the NICE guideline, which recommends that antidepressants are not routinely offered to people with dementia and depression, but that psychological treatments are considered instead. Share your views on the research. Why was this study needed? Dementia is a condition that includes memory loss, reasoning and communication difficulties, and changes in personality. It is progressive, so symptoms usually get worse. The most common types of dementia are Alzheimer’s disease

2019 NIHR Dissemination Centre

16. Aerobic exercise is an effective treatment for depression

Aerobic exercise is an effective treatment for depression Aerobic exercise is an effective treatment for depression Dissemination Centre Discover Portal NIHR DC Discover Aerobic exercise is an effective treatment for depression Published on 22 January 2019 doi: A systematic review shows aerobic exercise improves clinically diagnosed major depression compared with antidepressants or treatment as usual. Previous reviews found conflicting evidence of benefit. The new review only included (...) the trials thought to have the most applicable results. This meant that trials recruiting people who might not have a clinical diagnosis of depression or through media adverts were not considered. Also, studies were only included if they featured aerobic exercise – walking, jogging or using cardiovascular gym equipment rather than other activities such as stretching. Exercise is already recommended as a low-intensity psychological intervention in national guidance. Though the review only included 11

2019 NIHR Dissemination Centre

17. Combining mirtazapine with other antidepressants is not effective for treatment-resistant depression

Combining mirtazapine with other antidepressants is not effective for treatment-resistant depression Combining mirtazapine with other antidepressants is not effective for treatment-resistant depression Dissemination Centre Discover Portal NIHR DC Discover Combining mirtazapine with other antidepressants is not effective for treatment-resistant depression Published on 15 January 2019 doi: Adding mirtazapine to first-line antidepressants for adults with treatment-resistant depression does (...) not improve symptoms when compared with placebo (dummy pills). People taking mirtazapine are more likely to experience side effects, and stop taking their treatment. This NIHR-funded trial took place in 106 general practices in England, recruiting 480 adults with mild to severe depression. All participants had been taking selective serotonin reuptake inhibitor (SSRI) or serotonin-noradrenaline reuptake inhibitor (SNRI) antidepressants for at least six weeks but were still depressed. The findings show

2019 NIHR Dissemination Centre

18. A primary care intervention helps older people with depression

A primary care intervention helps older people with depression Signal - A primary care intervention helps older people with depression Dissemination Centre Discover Portal NIHR DC Discover A primary care intervention helps older people with depression Published on 23 January 2018 Enhanced case management (also called collaborative care) added to primary care reduced symptoms in people with clinical depression, compared with usual primary care. The benefit was similar to other depression (...) rolled-out to older people not using the Improving Access to Psychological Therapies programme. It is possible that greater treatment duration of the number of sessions might lead to longer-term impacts. These results have contributed to the draft NICE depression guideline out for consultation in 2017. Those with physical health and mobility problems and other barriers to using services may especially benefit. Share your views on the research. Why was this study needed? About one in seven people over

2019 NIHR Dissemination Centre

19. Collaborative care can be moderately effective at treating depression regardless of physical health status

Collaborative care can be moderately effective at treating depression regardless of physical health status Signal - Collaborative care can be moderately effective at treating depression regardless of physical health status Dissemination Centre Discover Portal NIHR DC Discover Collaborative care can be moderately effective at treating depression regardless of physical health status Published on 21 February 2017 Collaborative care can be moderately effective at treating depression compared (...) to usual care, whether or not people also have a long-term condition such as cancer or heart disease. Collaboration was provided by a case manager in primary care who was not a mental health professional. They coordinated a treatment plan with input from a GP and mental health professional. It is currently only recommended for people with depression and a long-term physical condition as prior to this review there was only consistent evidence of its effectiveness for people with both. This NIHR-funded

2019 NIHR Dissemination Centre

20. Collaborative mental health care in the NHS has small but meaningful benefits for people with depression

Collaborative mental health care in the NHS has small but meaningful benefits for people with depression Signal - Collaborative mental health care in the NHS has small but meaningful benefits for people with depression Dissemination Centre Discover Portal NIHR DC Discover Collaborative mental health care in the NHS has small but meaningful benefits for people with depression Published on 31 May 2016 Collaborative care, that places a care manager in primary care to deliver treatment (...) and coordinate care between GPs and specialists, improved recovery of people with moderate to severe depression. Primary responsibility for prescribing remained with the GP. This large trial found that improvements were modest, but were similar to those found in an evaluation of the Improving Access to Psychological Therapies programme. The collaborative care model was cost-effective too. Collaborative care cost on average £272.50 per participant and had a cost per quality-adjusted life year (QALY

Full Text available with Trip Pro

2019 NIHR Dissemination Centre